drugset / Trial / NCT00003641
High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Phase 3
Completed
1150 enrolled
ECOG-ACRIN Cancer Research Group
Cancer and Leukemia Group B · collabChildren's Oncology Group · collabNCIC Clinical Trials Group · collabNational Cancer Institute (NCI) · collabSWOG Cancer Research Network · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. It is not yet known whether treatment with interferon alfa is more effective than observation alone for stage II or stage III melanoma that has been completely removed surgically. PURPOSE: This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.
Timeline
- Start
- 1999-03-25
- Primary completion
- 2015-01
- Completion
- 2026-05-26
Outcome
Missed primary endpoint
registry analysis (unspecified test); Observation vs Interferon Alfa-2b; p = 0.964; Log Rank NCT00003641 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | interferon alfa-2b | Protein / enzyme biologic | — | Intravenous |